医学
利奈唑啉
低血糖
糖尿病
多药
内科学
蜂窝织炎
儿科
金黄色葡萄球菌
麻醉
胰岛素
外科
万古霉素
内分泌学
细菌
生物
遗传学
作者
Timothy W. Bodnar,Katelyn Starr,Jeffrey B. Halter
出处
期刊:American Journal of Geriatric Pharmacotherapy
日期:2011-02-01
卷期号:9 (1): 88-92
被引量:21
标识
DOI:10.1016/j.amjopharm.2011.02.002
摘要
Older diabetic patients are at increased risk for skin infections, often with methicillin-resistant Staphylococcus aureus (MRSA). Linezolid offers oral therapy with MRSA coverage. We present a case of linezolid-associated hypoglycemia in a 64-year-old diabetic patient with presumed MRSA cellulitis.A 64-year-old man with diabetes was treated for cellulitis. Linezolid was started when amoxicillin/clavulanate failed. Within 7 days, he developed frequent diaphoresis and tremulousness, with glucoses of 30 to 60 mg/dL. Hypoglycemia worsened despite decreasing insulin use, discontinuing glyburide, and increasing caloric intake. The day of admission, he awoke with a glucose level of 30 mg/dL. He took no medications, ate a large breakfast, and presented to clinic. He was symptomatic with a glucose level of 35 mg/dL. Hypoglycemia persisted despite IV dextrose. Linezolid was discontinued immediately in favor of vancomycin. Dextrose was weaned and his diabetes medications were resumed without further hypoglycemia.Linezolid has monoamine oxidase (MAO) inhibitory properties, and MAO inhibitors have been reported to contribute to hypoglycemia. The use of linezolid in older diabetic patients, especially those patients already taking agents with the potential to cause hypoglycemia, represents an area of concern. Increased comorbidities and polypharmacy in geriatric patients adds to this concern.
科研通智能强力驱动
Strongly Powered by AbleSci AI